Bank Of New York Mellon Corp Kaleido Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.05 - $1.7 $2,989 - $101,644	-59,791 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.3 - $2.7 $1,023 - $2,124	-787 Reduced 1.3%	59,791 $99,000
Q4 2021 Feb 11, 2022	SELL	$2.39 - $6.02 $44,779 - $112,790	-18,736 Reduced 23.62%	60,578 $145,000
Q3 2021 Nov 12, 2021	BUY	$5.36 - $7.99 $154,292 - $230,000	28,786 Added 56.97%	79,314 $433,000
Q2 2021 Aug 11, 2021	BUY	$5.82 - $8.72 $29,501 - $44,201	5,069 Added 11.15%	50,528 $375,000
Q1 2021 May 13, 2021	BUY	$7.2 - $16.82 $54,619 - $127,596	7,586 Added 20.03%	45,459 $368,000
Q4 2020 Feb 09, 2021	BUY	$5.77 - $11.33 $35,520 - $69,747	6,156 Added 19.41%	37,873 $344,000
Q3 2020 Nov 12, 2020	SELL	$5.09 - $11.07 $9,976 - $21,697	-1,960 Reduced 5.82%	31,717 $351,000
Q2 2020 Aug 12, 2020	SELL	$4.62 - $8.01 $4,814 - $8,346	-1,042 Reduced 3.0%	33,677 $250,000
Q1 2020 May 06, 2020	BUY	$3.62 - $9.49 $13,553 - $35,530	3,744 Added 12.09%	34,719 $213,000
Q4 2019 Feb 14, 2020	BUY	$5.02 - $8.87 $68,919 - $121,776	13,729 Added 79.61%	30,975 $155,000
Q3 2019 Nov 07, 2019	BUY	$6.74 - $11.3 $116,238 - $194,879	17,246 New	17,246 $129,000

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.